An die calypte-geschädigten

Healthcare & Biotechnology Investment Conference

Please mark on your calendar and attend on January 22nd at the San Francisco Omni Hotel our next Healthcare & Biotechnology conference of companies covered by JM Dutton & Associates.  This conference follows our very successful September 24th New York City Healthcare and Biotechnology conference with over 220 in attendance.  

We expect approximately 12 companies to present from the list of our covered Healthcare and Biotechnology companies.  These leading small cap biotechnology companies include:

Neurobiological Technologies – Nasdaq: NTII
Aastrom Biosciences – Nasdaq: ASTM
Isolagen – AMEX: ILE
GlycoGenesys – Nasdaq: GLGS
Calypte Biomedical Corp - OTCBB: CYPT
AP Pharma – Nasdaq: APPA
BioSante – AMEX: BPA
Draxis Health Inc – Nasdaq: DRAX
Pharmos – Nasdaq: PARS
Physiometrix – Nasdaq: PHYX

Our research on most all of the above companies can be found on our site at www.jmdutton.com, while our initiating coverage on a few attending companies should be available shortly.

Tickets for the event at no cost for qualified institutional and other investors can be obtained by clicking here:   www.friedlandcapital.com/Dutton.htm.  The conference is administered for us by Friedland Capital.

The January 2004 edition of Buyside Magazine points out, JM Dutton & Associates was ranked the top independent research provider in the US among a list of the the top 18 independent providers. This was a ranking based on research performance and other factors, including analyst quality and experience.  Based on the Investars results, a third party statistical monitoring firm covering the 120 major Wall Street research firms, we were ranked in the top quartile of the 10 industries tracked by Investars, including healthcare and biotechnology.  Based on Investars' evaluation, JM Dutton & Associates ranked in the top 10% of the 111 Wall Street firms monitored during the past two years. The article can be read by clicking here.
We look forward to seeing you at our conference.

John M. Dutton
JM Dutton & Associates, LLC
Independent Investment Research
San Francisco  Los Angeles  New York  London
t.  (916) 941-8119   f. (916) 941-8093
c. (310) 717-3576
jmdutton@jmdutton.com  www.jmdutton.com

 

ach was.... warum denn nun solche toene ?

 

Gruss,

Parocorp

_________________________________

*klick* Alle relevanten Wirtschaftstermine als Desktop-Hintergrund *klick*

 

an Caly verdient?
Offensichtlich meislo nicht...  

genauso ist es bei gewinne.  

investiert war und es auch nie sein werde!

ich glaube halt nicht an deren marktpotential. dafür hat die aktie in der vergangenheit einfach zu sehr enttäuscht und niemals dass eingehalten was sich investoren versprochen haben.

gruss meislo  

zu realisieren.

Lieber ein ende mit schrecken als ein schrecken ohne ende.
gruss meislo  

jeder wie er glaubt.